17-beta-hydroxywithanolides and use thereof in treating cancer
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Arizona Board of Regents on Behalf of the University of Arizona
InventorsThomas J. Sayers, Poonam Tewary, Leslie Gunatilaka, Alan D. Brooks, Kithsiri Wijeratne, Yaming Xu
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds suitable for enhancing cancer treatment, for example, a compound of formula (I): (I) wherein R1 is as defined herein. Also disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, a method of inducing apoptosis in cancer cells in a mammal, and a method of treating prostate cancer in mammal in need thereof comprising administration of a compound described herein.
Claims10
A compound of formula (I):
- wherein R1 is C3-C10 alkyl, C3-C8 cycloalkyl, C6-C10 aryl, C6-C10 aryl-C1-C10 alkyl, C6-C10 aryl-C2-C10 alkenyl, monocyclic heteroaryl, bicyclic heteroaryl, monocyclic heteroaryl-C1-C10 alkyl, bicyclic heteroaryl-C1-C10 alkyl, or 4-alkylenyl-tetrahydro-1H-thieno[3,4-d]imidazol-2(3H)-one,
- wherein the aryl or heteroaryl portion of R1 is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, aryl, thioalkoxy, heterocyclyl, and nitro.
Dependencies are inferred from the claim text.